ZNF703 Antibody, HRP conjugated

Code CSB-PA026966LB01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) ZNF703 Polyclonal antibody
Uniprot No.
Target Names
ZNF703
Alternative Names
FLJ14299 antibody; ZEPPO1 antibody; Zinc finger elbow-related proline domain protein 1 antibody; Zinc finger protein 703 antibody; ZN703_HUMAN antibody; ZNF503L antibody; znf703 antibody; ZPO1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Zinc finger protein 703 protein (218-286AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
HRP
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Transcriptional corepressor which does not bind directly to DNA and may regulate transcription through recruitment of histone deacetylases to gene promoters. Regulates cell adhesion, migration and proliferation. May be required for segmental gene expression during hindbrain development.
Gene References into Functions
  1. ZNF703 can potently facilitate tumor growth and metastasis in many respects throughout the progression of CCA, which may act as an oncogene in CCA and can be considered as a novel potential therapeutic target. PMID: 27764785
  2. ZNF703 activated the PI3K/AKT/GSK-3beta signalling pathway and its downstream effectors, thus regulating the cell cycle and epithelial-mesenchymal transition. PMID: 29176314
  3. Results show that ZNF703 is up-regulated in 63.4% of non-small cell lung cancer (NSCLC) tumor samples and it may contribute to tumor development by activating the Akt/mTOR pathway in NSCLC. PMID: 27650486
  4. In vitro function assays demonstrated that SPRY4-IT1 cause promotion of cell viability in ESCC cells. Authors further verified that SPRY4-IT1 could also activate the expression of ZNF703 in ESCC cells, which might contribute to the role of SPRY4-IT1 in ESCC cells. PMID: 27453415
  5. Results show that ZNF703 overexpression is associated with adverse prognosis in head and neck squamous cell carcinomas, which might be a novel biomarker for this type of neoplasm. PMID: 26063961
  6. ZNF703 was a target of SPRY4-IT1. PMID: 25742952
  7. Results show that ZNF703 expression is upregulated in colorectal cancer tissues (CRC) and is significantly correlated with tumor size, pathological grading, and serosal and lymph node metastasis suggesting that it may act as an oncogene in CRC. PMID: 25017610
  8. The results showed that ZNF703 acts as a gastric cancer oncogene PMID: 24481460
  9. High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. PMID: 24156016
  10. Data indicate that ZNF703 overexpression in MCF-7 breast cancer cells activated the Akt/mTOR signaling pathway, downregulated ERalpha, and reduced the antitumor effect of tamoxifen. PMID: 23991038
  11. The conserved domains are essential for proper subcellular localization and transcriptional repression of the NLZ1/ZNF703 protein. PMID: 22886885
  12. ZNF703 expression results in the activation of stem cell-related gene expression leading to an increase in cancer stem cells. PMID: 21328542
  13. These data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer. PMID: 21337521
  14. Data show that FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53. PMID: 19330026

Show More

Hide All

Involvement in disease
Luminal B breast cancers are the clinically more aggressive estrogen receptor-positive tumors. Amplification of a distal 8p12 locus occurs in around one third of the cases and ZNF703 is the single gene within the minimal amplicon. Amplification of the gene correlates with its protein expression in tumor cells. ZNF703 is a classical breast cancer oncogene since it is able to transform non-malignant cells and increase cellular proliferation.
Subcellular Location
Nucleus. Cytoplasm.
Protein Families
Elbow/Noc family
Tissue Specificity
Expressed in mammary epithelium.
Database Links

HGNC: 25883

KEGG: hsa:80139

STRING: 9606.ENSP00000332325

UniGene: Hs.288042

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*